(Q51834159)

13 April 2018

title

Systemic lupus erythematosus. (English)

1 reference

13 April 2018

author

David A. Isenberg

series ordinal

3

1 reference

13 April 2018

author name string

Larissa Lisnevskaia

series ordinal

1

1 reference

13 April 2018

Grainne Murphy

series ordinal

2

1 reference

13 April 2018

language of work or name

English

0 references

publication date

31 May 2014

1 reference

13 April 2018

published in

The Lancet

1 reference

13 April 2018

volume

384

1 reference

13 April 2018

page(s)

1878-1888

1 reference

13 April 2018

issue

9957

1 reference

13 April 2018

Systemic lupus erythematosus

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Male versus female lupus: a comparison of ethnicity, clinical features, serology and outcome over a 30 year period

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Mortality in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Changing worldwide epidemiology of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Immunopathogenic mechanisms of systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

The genetics of lupus: a functional perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Disturbances of apoptotic cell clearance in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Mechanisms of B cell autoimmunity in SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Abnormalities of T cell signaling in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Cytokine disturbances in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Environment and lupus-related diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Vitamin D in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Anti-TNF-induced lupus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Reproductive and menopausal factors and risk of systemic lupus erythematosus in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Cyclophosphamide and lupus nephritis: when, how, for how long?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Neuropsychiatric systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

New autoantigens in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Atherosclerosis in thrombotic primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Therapeutic strategies in antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

A new dawn of anticoagulation for patients with antiphospholipid syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Potential use of statins in the treatment of antiphospholipid syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Statins for the treatment of antiphospholipid syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Use of rituximab in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Lupus activity in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Managing lupus patients during pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Lupus nephritis and pregnancy in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Hydroxychloroquine: the cornerstone of lupus therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Azathioprine therapy for patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Methotrexate in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Cyclosporine (CsA) in lupus nephritis: assessing the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Topical calcineurin inhibitors in cutaneous lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Leflunomide: a drug with a potential beyond rheumatology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Belimumab: in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

The discovery and development of belimumab: the anti-BLyS-lupus connection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Treatment of systemic lupus erythematosus with epratuzumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Abatacept in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Anti-interferon alpha treatment in SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Social support and health in patients with systemic lupus erythematosus: a literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

Supervised physical exercise improves endothelial function in patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960128-8

7 January 2021

10.1016/S0140-6736(14)60128-8

Identifiers

DOI

1 reference

13 April 2018

PubMed ID

24881804

1 reference

13 April 2018